| Literature DB >> 29923255 |
Mingli Han1,2, Yimeng Wang3, Guangcheng Guo1, Lin Li1, Dongwei Dou1,2, Xin Ge1, Pengwei Lv1, Fang Wang1, Yuanting Gu1.
Abstract
miR-30d has been shown to play pivotal roles in cancer development, and has the potential to act as a diagnostic biomarker and therapeutic target in breast cancer. However, the specific function and molecular mechanism of miR-30d in breast cancer cell growth and metastasis is still unknown. The present study seeks to shed light on the potential contribution of the MiR-30d-KLF-11-STAT3 pathway in breast cancer. The results revealed that miR-30d levels were markedly increased in the breast cancer cell lines BT474, MDA-MB-231, HCC197, and MDA-MB-468 compared with the non-tumor mammary gland MCF10A cell line. Furthermore, the miR-30d mimic increased BT474 and MDA-MB-231 breast cancer cell survival, inhibited apoptosis and increased Bcl-2 expression, whilst inhibited Bax protein levels. miR-30d mimics promote BT474 and MDA-MB-231 cell migration, invasion, and mediate the EMT phenotype. However, miR-30d inhibitors reverse all of the effects of miR-30d mimics on breast cancer cell biology. Also, we observed that KLF-11 is a direct target of miR-30d and KLF-11 and pSTAT3 expression are determined by miR-30d. Finally, the results suggest that miR-30d plays essential roles in breast cancer cells in a manner that is dependent on the levels of KLF-1 and pSTAT3. In summary, miR-30d appears to be a novel diagnostic biomarker and treatment target in breast cancer.Entities:
Keywords: EMT; KLF-11; breast cancer; metastasis; miR-30d; pSTAT3
Mesh:
Substances:
Year: 2018 PMID: 29923255 DOI: 10.1002/jcb.26767
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429